EndoParagon Inc. was founded by Dr. Deborah A. Nicoll-Griffith.
After undergraduate studies in Biochemistry, Deborah studied at the University of British Columbia in Canada where she earned a Ph.D. in Synthetic Organic Chemistry.
Following two post-doctoral fellowships, she started her career in the pharmaceutical industry where she worked as both a senior scientist and executive for over 25 years. She served at the Merck Frosst Centre for Therapeutic Research (Kirkland, Québec) as a Senior Director and she also worked at Merck & Co (New Jersey, USA) for over six years. From the US she led multi-site, multi-national corporate project teams and external R&D projects related to infectious diseases with partners on four continents.
During the span of her career, she has played key roles in the Discovery and Early Development of five marketed drugs and numerous pre-clinical and clinical drug candidates. She has acquired and applied a broad knowledge of the sciences related to pharmaceutical R&D including bioanalytical, biochemistry, synthetic organic chemistry, drug metabolism, pharmacokinetics, pharmacodynamics, toxicology, infectious diseases biology and infectious diseases in vivo pharmacology.
Deborah has an extensive publication record. She is internationally recognized in several scientific fields and, within the last decade, she has established a solid reputation for leadership in Chagas' disease drug research.
She is fluent in English and French, and has a reading knowledge of Portuguese and Spanish.